SCHEMBL5160478

SCHEMBL5160478

CCN(CC)C(=O)CC(=O)c1cncnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.41
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
BDKRB1 P46663 1/20 0.38
PLOD2 O00469 1/20 0.35
PRMT3 O60678 1/20 0.35
MAPT P10636 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GFER P55789 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5157970 0.81 HCAR2 (0.43) HCAR2ALDH1A1KDM4EPLOD2PRMT3
SCHEMBL5160016 0.80 PLOD2 (0.61) HCAR2LMNAALDH1A1KDM4EPLOD2
SCHEMBL5160489 0.79 ALDH1A1 (0.55) LMNAALDH1A1KDM4EPLOD2PRMT3
SCHEMBL27690353 0.77 HPGD (0.47) HCAR2LMNAALDH1A1BDKRB1MAPT
SCHEMBL5158494 0.75 ALDH1A1 (0.51) HCAR2ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL5163272 0.75 ACACB (0.39) LMNAALDH1A1KDM4ENPC1RAB9A
SCHEMBL6249575 0.74 HCAR2 (0.52) HCAR2KDM4EPLOD2MAPTSMN1; SMN2
SCHEMBL10607038 0.74 HPGD (0.59) LMNAALDH1A1KDM4EPLOD2MAPT
SCHEMBL5164294 0.73 HCAR2 (0.42) HCAR2ALDH1A1PLOD2HDAC3HDAC1
SCHEMBL5159804 0.72 HCAR2 (0.45) HCAR2ALDH1A1KDM4EPLOD2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO HCAR2 12/4885LMNA 3165/4885ALDH1A1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.